시장보고서
상품코드
1193083

펩티드 치료제 시장 : 용도별, 투여 경로별, 유통 채널별 - 세계 기회 분석 및 산업 예측(2021-2031년)

Peptide Therapeutics Market By Application, By Route of administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 309 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

펩티드 치료제의 세계 시장은 2021년에 332억 5772만 달러가 되었고, 2031년에는 643억 3612만 달러에 이르며 2022년부터 2031년에 걸쳐 CAGR 6.8%로 성장할 것으로 예측되고 있습니다.

펩티드는 아미노산이 화학적으로 결합된 작은 사슬이며, 일반적으로 2개 내지 50개의 아미노산이 결합된다(펩티드 결합이라고 함). 펩티드는 단백질보다 작고 2-50개 정도의 아미노산으로 구성되어 있습니다. 펩티드를 질병의 치료에 이용하는 것을 펩티드 치료라고 합니다. 펩티드 치료는 자연 발생 펩티드가 호르몬, 성장 인자, 이온 채널 리간드, 항효과 등의 역할을 하는 것을 재현하는 것입니다. 펩티드가 신체에서 대사 될 수 있다는 것을 감안할 때, 펩티드 치료제는 일반적으로 안전하고 좋은 tolerated.The 주요 요인은 펩티드 치료제에 대한 연구 및 개발, 당뇨병, 암, 펩타이드 치료 약물의 대폭적인 개발 및 성장과 같은 만성 질환의 발병률의 증가는 펩티드 치료제 시장의 성장으로 인한 요인으로 간주됩니다. 게다가 주요 선수들에 의한 R&D의 급증은 시장의 주요 동향이며 예측 기간 동안 성장을 촉진할 것으로 기대된다.

만성 질환의 유병률 증가는 펩티드 치료제 시장을 견인합니다. 예를 들어 NCBI(국립생물공학정보센터)에 따르면 소화기계 질환은 미국에서 매년 추정 6000만-7000만 명에 영향을 주며 미국 남성과 여성 사이에서 진단되는 2위 암 로 대장암이 있습니다. 이와 같이 세계적으로 만성질환의 유병률이 증가하고 있으며, 펩티드 치료제의 필요성이 더욱 높아지고 시장의 성장을 일으키고 있다.

그러나 펩티드의 생체이용률이 낮고 약물 개발에 드는 비용이 시장 성장을 방해할 것으로 예상됩니다. 한편, 소비자의 요구를 충족시키는 신흥 시장의 성장 기회는 투자자에게 큰 투자 기회가 될 것으로 예상됩니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 개요

  • 시장의 정의와 범위
  • 주요 조사 결과
    • 주요 투자 포켓
  • Porter's Five Forces 분석
  • 주요 기업의 포지셔닝
  • 시장 역학
    • 촉진 요인
    • 억제 요인
    • 기회
  • COVID-19 영향 분석
  • 특허 상황

제4장 펩티드 치료제 시장 : 응용 분야별

  • 개요
    • 시장 규모 및 예측
  • 대사
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 온콜로지
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 소화기
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 신경
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 순환기
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 기타
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별

제5장 펩티드 치료제 시장 : 투여 경로별

  • 개요
    • 시장 규모 및 예측
  • 경구
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 비경구제
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별

제6장 펩티드 치료제 시장 : 유통 채널별

  • 개요
    • 시장 규모·예측
  • 병원 약국
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
    • 병원 약국 펩티드 치료제 시장 : 병원 유형별
      • 프라이빗 시장 규모·예측 : 지역별
      • 공적 시장 규모·예측 : 지역별
  • 약국, 소매 약국
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 온라인 약국
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별

제7장 펩티드 치료제 시장 : 지역별

  • 개요
    • 시장 규모·예측
  • 북미
    • 주요 동향과 기회
    • 북미 시장 규모·예측 : 용도별
    • 북미 시장 규모·예측 : 투여 경로별
    • 북미 시장 규모·예측 : 유통 채널별
      • 북미의 병원 약국 펩티드 치료제 시장 : 병원 유형별
    • 북미 시장 규모·예측 : 국가별
      • 미국
      • 캐나다
      • 멕시코
  • 유럽
    • 주요 동향과 기회
    • 유럽의 시장 규모·예측 : 용도별
    • 유럽 시장 규모·예측 : 투여 경로별
    • 유럽 시장 규모·예측 : 유통 채널별
      • 유럽 병원 약국 펩티드 치료제 시장 : 병원 유형별
    • 유럽 시장 규모·예측 : 국가별
      • 독일
      • 프랑스
      • 영국
      • 이탈리아
      • 스페인
      • 기타 유럽
  • 아시아태평양
    • 주요 동향과 기회
    • 아시아태평양의 시장 규모·예측 : 용도별
    • 아시아태평양지역의 시장 규모·예측 : 투여경로별
    • 아시아태평양의 시장 규모·예측 : 유통 채널별
      • 아시아태평양의 병원 약국용 펩티드 치료제 시장 : 병원 유형별
    • 아시아태평양의 시장 규모·예측 : 국가별
      • 일본
      • 중국
      • 인도
      • 호주
      • 한국
      • 기타 아시아태평양
  • LAMEA
    • 주요 동향과 기회
    • LAMEA의 시장 규모·예측 : 용도별
    • LAMEA의 시장 규모·예측 : 투여경로별
    • LAMEA의 시장 규모·예측 : 유통채널별
      • LAMEA의 병원 약국용 펩티드 치료제 시장 : 병원 유형별
    • LAMEA의 시장 규모·예측 : 국가별
      • 브라질
      • 사우디아라비아
      • 남아프리카
      • 기타 LAMEA 지역

제8장 기업 정세

  • 소개
  • 주요 성공 전략
  • 주요 10개사의 제품 매핑
  • 경쟁 대시보드
  • 경합의 히트 맵
  • 주요 발전

제9장 기업 프로필

  • Eli Lilly and Company
  • Amgen Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Novo Nordisk A/S
  • Sanofi SA
  • Ever Neuro Pharma GmbH
  • Baush Health
  • GlaxoSmithKline plc
  • Abbvie(Allergan)
ksm 23.03.27

The global peptide therapeutics market was valued at $33,257.72 million in 2021, and is estimated to reach $64,336.12 million by 2031, growing at a CAGR of 6.8% from 2022 to 2031. A peptide is a small, chemically bound chain of amino acids, usually between two and fifty amino acids (called peptide bonds). Peptides are smaller than proteins, consisting of about 2 to 50 amino acids. Peptides employed in the therapy of diseases are known as peptide therapies. Peptide treatments replicate such roles that naturally occurring peptides can perform as hormones, growth factors, ion channel ligands, and anti-effectiveness. Given that peptides can be metabolized by the body, peptide therapeutics are thought to be generally safe and well-tolerated.The major factors that drive the growth of the peptide therapeutics market are rise in incidence of chronic diseases such as diabetes, cancer, significant development of peptide therapeutics and growth in R & D for peptide therapeutics, are the factors attributed to the growth of the peptide therapeutics market. In addition, surge in the R & D by the key players is a key trend of the market, which is expected to fuel the growth in the forecast period.

Rise in prevalence of the chronic diseases drives peptide therapeutics market. For an instance, according to the NCBI, National Center for Biotechnology Information, gastrointestinal diseases affect an estimated 60 to 70 million people annually in America and having colorectal cancer as the 2nd leading cancer diagnosed among American men and women. Thus, globally, there has been an increase in prevalence of chronic diseases. which further highlights the need for the peptide therapeutics causing the market growth.

However, poor bioavailability of peptides and high cost associated with drug development are expected to hinder the growth of the market. Conversely, growth opportunities in emerging market to suffice the consumer demands is expected to provide a great opportunity for the investors to invest in the market.

The global peptide therapeutics market is segmented on the basis of application, route of administration, distribution channel, and region. On the basis of application, the market is categorized into metabolic, oncology, gastrointestinal, neurological, cardiovascular and others. By route of administration, it is divided into oral and parenteral. By distribution channel, it is segmented into hospital pharmacies, drug store & retail pharmacies and online pharmacies. Hospital pharmacies segment is further bifurcated as private and public. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).

The major players profiled in the report are AbbVie Inc, Amgen Inc., Bausch Health Companies Inc, Eli Lilly and company, Ever Neuro Pharma GmbH, GalaxoSmithKline plc, Novo Nordisk, Pfizer Inc, Sanofi-GSK and Takeda Pharmaceutical Company Limited.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the peptide therapeutics market analysis from 2021 to 2031 to identify the prevailing peptide therapeutics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the peptide therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global peptide therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Application

  • Metabolic
  • Oncology
  • Gastrointestinal
  • Neurological
  • Cardiovascular
  • Others

By Route of administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital pharmacies
    • Hospital type
    • Private
    • Public
  • Drug store and retail pharmacies
  • Online pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • Eli Lilly and Company
    • Amgen Inc.
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • Novo Nordisk A/S
    • Sanofi SA
    • Ever Neuro Pharma GmbH
    • Baush Health
    • GlaxoSmithKline plc
    • Abbvie ( Allergan)

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market
  • 3.7.Patent Landscape

CHAPTER 4: PEPTIDE THERAPEUTICS MARKET, BY APPLICATION

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Metabolic
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Oncology
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Gastrointestinal
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 Neurological
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country
  • 4.6 Cardiovascular
    • 4.6.1 Key market trends, growth factors and opportunities
    • 4.6.2 Market size and forecast, by region
    • 4.6.3 Market analysis by country
  • 4.7 Others
    • 4.7.1 Key market trends, growth factors and opportunities
    • 4.7.2 Market size and forecast, by region
    • 4.7.3 Market analysis by country

CHAPTER 5: PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Oral
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Parenteral
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country

CHAPTER 6: PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
    • 6.2.4 Hospital pharmacies Peptide Therapeutics Market by Hospital type
      • 6.2.4.1 Private Market size and forecast, by region
      • 6.2.4.2 Public Market size and forecast, by region
  • 6.3 Drug store and retail pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Online pharmacies
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: PEPTIDE THERAPEUTICS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Application
    • 7.2.3 North America Market size and forecast, by Route of administration
    • 7.2.4 North America Market size and forecast, by Distribution Channel
      • 7.2.4.1 North America Hospital pharmacies Peptide Therapeutics Market by Hospital type
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Application
      • 7.2.5.1.2 Market size and forecast, by Route of administration
      • 7.2.5.1.3 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Application
      • 7.2.5.2.2 Market size and forecast, by Route of administration
      • 7.2.5.2.3 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Application
      • 7.2.5.3.2 Market size and forecast, by Route of administration
      • 7.2.5.3.3 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Application
    • 7.3.3 Europe Market size and forecast, by Route of administration
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
      • 7.3.4.1 Europe Hospital pharmacies Peptide Therapeutics Market by Hospital type
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Application
      • 7.3.5.1.2 Market size and forecast, by Route of administration
      • 7.3.5.1.3 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Application
      • 7.3.5.2.2 Market size and forecast, by Route of administration
      • 7.3.5.2.3 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Application
      • 7.3.5.3.2 Market size and forecast, by Route of administration
      • 7.3.5.3.3 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Application
      • 7.3.5.4.2 Market size and forecast, by Route of administration
      • 7.3.5.4.3 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Application
      • 7.3.5.5.2 Market size and forecast, by Route of administration
      • 7.3.5.5.3 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Application
      • 7.3.5.6.2 Market size and forecast, by Route of administration
      • 7.3.5.6.3 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Application
    • 7.4.3 Asia-Pacific Market size and forecast, by Route of administration
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
      • 7.4.4.1 Asia-Pacific Hospital pharmacies Peptide Therapeutics Market by Hospital type
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Application
      • 7.4.5.1.2 Market size and forecast, by Route of administration
      • 7.4.5.1.3 Market size and forecast, by Distribution Channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Application
      • 7.4.5.2.2 Market size and forecast, by Route of administration
      • 7.4.5.2.3 Market size and forecast, by Distribution Channel
      • 7.4.5.3 India
      • 7.4.5.3.1 Market size and forecast, by Application
      • 7.4.5.3.2 Market size and forecast, by Route of administration
      • 7.4.5.3.3 Market size and forecast, by Distribution Channel
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Market size and forecast, by Application
      • 7.4.5.4.2 Market size and forecast, by Route of administration
      • 7.4.5.4.3 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Application
      • 7.4.5.5.2 Market size and forecast, by Route of administration
      • 7.4.5.5.3 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Application
      • 7.4.5.6.2 Market size and forecast, by Route of administration
      • 7.4.5.6.3 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Application
    • 7.5.3 LAMEA Market size and forecast, by Route of administration
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
      • 7.5.4.1 LAMEA Hospital pharmacies Peptide Therapeutics Market by Hospital type
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Application
      • 7.5.5.1.2 Market size and forecast, by Route of administration
      • 7.5.5.1.3 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Application
      • 7.5.5.2.2 Market size and forecast, by Route of administration
      • 7.5.5.2.3 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Application
      • 7.5.5.3.2 Market size and forecast, by Route of administration
      • 7.5.5.3.3 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Application
      • 7.5.5.4.2 Market size and forecast, by Route of administration
      • 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Eli Lilly and Company
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Amgen Inc.
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Pfizer Inc.
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Takeda Pharmaceutical Company Limited
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Novo Nordisk A/S
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Sanofi SA
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Ever Neuro Pharma GmbH
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Baush Health
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 GlaxoSmithKline plc
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Abbvie ( Allergan)
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제